PMID- 31616499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1758-3780 (Electronic)
IS  - 1758-3772 (Print)
IS  - 1758-3772 (Linking)
VI  - 15
IP  - 2
DP  - 2019 Aug
TI  - Metastatic MEN1 Syndrome Treated with Lutetium-177 - A Case Report.
PG  - 92-94
LID - 10.17925/EE.2019.15.2.92 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine 
      tumour syndrome characterised by three main manifestations: primary 
      hyperparathyroidism (78-94%), gastroenteropancreatic neuroendocrine tumours 
      (GEP-NETs) (35-78%) and pituitary adenomas (20-65%). For metastatic and 
      inoperable GEP-NETs, there are some interventional and medical therapies. Peptide 
      receptor radionuclide therapy (PRRT) with Yttrium-90 ((90)Y) and Lutetium-177 
      ((177)Lu) is one of the important radiotherapies. Herein we describe a case of 
      MEN1 syndrome with inoperable metastatic GEP-NETs who had excellent response to 
      the treatment with six cycles of (177)Lu-DOTATATE. The patient was admitted to 
      our clinic with widening of hands and feet, polyuria, polydipsia, nausea, 
      vomiting and constipation. His laboratory and screening findings were consistent 
      with primary hyperparathyroidism, acromegaly, secondary hypogonadism and central 
      diabetes insipidus. He underwent 3.5 parathyroidectomy and hypophysis 
      adenomectomy. Under treatment with lanreotide and cabergoline, he developed 
      metastatic duodenal NET. PRRT with (177)Lu-DOTATATE was administered in six 
      cycles and an excellent response was displayed without any side effect. In 
      conclusion, the dramatic response of the patient to PRRT with (177)Lu-DOTATATE, 
      described in our case report and recent published articles indicating the 
      beneficial efficacy and limited adverse effects of (177)Lu-DOTATATE, should 
      encourage clinicians to use PRRT for inoperable or metastatic NETs.
CI  - (c) The Author(s) 2019.
FAU - Gezer, Emre
AU  - Gezer E
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
FAU - Cetinarslan, Berrin
AU  - Cetinarslan B
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
FAU - Canturk, Zeynep
AU  - Canturk Z
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
FAU - Tarkun, IIlhan
AU  - Tarkun I
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
FAU - Sozen, Mehmet
AU  - Sozen M
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
FAU - Selek, Alev
AU  - Selek A
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli 
      University, Kocaeli, Turkey.
LA  - eng
PT  - Case Reports
DEP - 20190816
PL  - England
TA  - Eur Endocrinol
JT  - European endocrinology
JID - 101574781
PMC - PMC6785959
OTO - NOTNLM
OT  - Lutetium
OT  - MEN1 syndrome
OT  - metastasis
OT  - neuroendocrine tumor
COIS- Disclosure: Emre Gezer, Berrin Cetinarslan, Zeynep Canturk, Ilhan Tarkun, Mehmet 
      Sozen and Alev Selek have nothing to declare in relation to this article.
EDAT- 2019/10/17 06:00
MHDA- 2019/10/17 06:01
PMCR- 2019/08/01
CRDT- 2019/10/17 06:00
PHST- 2019/03/05 00:00 [received]
PHST- 2019/04/18 00:00 [accepted]
PHST- 2019/10/17 06:00 [entrez]
PHST- 2019/10/17 06:00 [pubmed]
PHST- 2019/10/17 06:01 [medline]
PHST- 2019/08/01 00:00 [pmc-release]
AID - 10.17925/EE.2019.15.2.92 [doi]
PST - ppublish
SO  - Eur Endocrinol. 2019 Aug;15(2):92-94. doi: 10.17925/EE.2019.15.2.92. Epub 2019 
      Aug 16.